ArticleThe Annals of thoracic surgery2025
Assessing the Efficacy of Pathogen-Reduced Platelet Transfusions for Hemostasis in Children Undergoing Cardiopulmonary Bypass Surgery.
Article in The Annals of thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundChildren undergoing cardiopulmonary bypass (CPB) surgery are vulnerable to bleeding and often require transfusions. Pathogen-reduced (PR) platelets may reduce microbial contamination but are associated with decreased platelet count increments and increased transfusions. We sought to evaluate hemostasis in children undergoing CPB surgery receiving PR platelets vs large-volume delayed sampling (LVDS) platelets.
methodsWe performed a retrospective review of children in a cardiac intensive care unit after CPB surgery from 2020 to 2022. Demographics, operative characteristics, transfusion details, and outcomes were compared. The primary outcome was postoperative chest tube bleeding in the first 24 hours.
resultsThere were 522 patients enrolled; 47% (243/522) received LVDS platelets and 53% (279/522) received PR platelets. Median (interquartile range) age was 4 (0-29) months. There were no differences in age (P = .499) or The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery congenital heart surgery mortality score (P = .813). There were no differences between platelet groups in postoperative chest tube bleeding at 1 hour (2.9 vs 3.2 mL/kg; P = .179), 2 hours (4.9 vs 5.1 mL/kg; P = .368), 4 hours (7.7 vs 8.1 mL/kg; P = .433), 8 hours (11.9 vs 12.9 mL/kg; P = .610), 12 hours (17.0 vs 17.1 mL/kg; P = .966), or 24 hours (28.0 vs 27.0 mL/kg; P = .536) after surgery. There were also no differences in doses of red blood cells (P = .054), cell salvage (P = .220), plasma (P = .337), or cryoprecipitate (P = .091).
conclusionsChildren who received PR platelets had the same amount of chest tube output and did not require increased transfusions compared with LVDS platelet recipients. In children undergoing CPB surgery, PR platelets appeared to provide adequate hemostasis with further theoretical benefit of reduced microbial contamination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.